>Wouldn't exactly be a shock if KERX's CEO was fudging the figures on its clinical trial. That's pretty much what CEO's do. They are after all paid promoters and Weiss appears to be superb at the job.<
As with the issue of interim looks (#msg-8530993), this is a matter of degree. I happen to think that the KRX-101 data are a little messy, even for a phase-2 trial.
Moreover, as a rule I have a hard time accepting the notion that a savant like Michael Weiss, Esq., has salvaged a blockbuster-in-waiting from the scrap heap. Yes, these things do happen occasionally, but most prospective blockbusters have little trouble finding funding without the intervention of a Weiss-like promoter. JMHO, FWIW
Market Data 
Markets 
AI
